Live Analyst Rating Changes 1515 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/Jack Allen
BAIRD
Jack Allen
Robert W. Baird
Wall Street Analyst
★★★☆☆
#1800
on 13Foresight · ranked by our own returns
50%
Success Rate
+16.8%
Average Return
10 of 20 calls profitable · +0.9% vs benchmark
📈 Across the calls we could measure, roughly 50% of Jack Allen's ratings turned a profit when each position was held for 1 year — averaging +16.8% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

12 Buy 8 Hold 0 Sell
Jack's Stock Coverage 20 ratings · 2026-06-19
Company Date Position Consensus ⓘ Price Target ⓘ 1-Yr Return
LYEL
Lyell Immunopharma
 May 01, 2026 BUY Buy
+96.5% avg upside
10 analysts
$49.00
284.61% Upside
 -42.5%
NTLA
Intellia Therapeutics
 Apr 27, 2026 HOLD Buy
+153.7% avg upside
37 analysts
$13.00
16.99% Downside
 -7.1%
ALLO
Allogene Therapeutics
 Apr 14, 2026 BUY Strong Buy
+662.8% avg upside
28 analysts
$9.00
349.96% Upside
 -16.7%
RARE
Ultragenyx Pharmaceutical
 Feb 13, 2026 BUY Strong Buy
+142.0% avg upside
36 analysts
$40.00
45.72% Upside
 +12.6%
TIL
Instil Bio
 Jan 07, 2026 HOLD Buy
+343.4% avg upside
8 analysts
$7.00
6.66% Downside
 +6.3%
MREO
Mereo Biopharma Group Plc
 Dec 29, 2025 BUY Strong Buy
+1146.9% avg upside
11 analysts
$1.00
223.15% Upside
 -14.3%
VOR
Vor Biopharma
 Dec 23, 2025 BUY Buy
+199.3% avg upside
17 analysts
$46.00
217.53% Upside
 +4.0%
CRSP
Crispr Therapeutics AG
 Nov 11, 2025 HOLD Buy
+39.7% avg upside
41 analysts
$44.00
18.59% Downside
 -5.8%
TSHA
Taysha Gene Therapies
 Oct 02, 2025 BUY Strong Buy
+103.3% avg upside
21 analysts
$12.00
86.82% Upside
 +26.8%
LCTX
Lineage Therap
 Sep 23, 2025 BUY Strong Buy
+342.7% avg upside
16 analysts
$5.00
313.19% Upside
 -23.9%
EDIT
Editas Medicine
 Aug 13, 2025 BUY Buy
+420.3% avg upside
33 analysts
$6.00
122.98% Upside
 -14.1%
VYGR
Voyager Therapeutics
 Jul 17, 2025 BUY Strong Buy
+284.7% avg upside
23 analysts
$18.00
383.80% Upside
 +8.7%
FATE
Fate Therapeutics
 May 14, 2025 HOLD Buy
+492.3% avg upside
31 analysts
$4.00
91.32% Upside
 +97.9%
INKT
MiNK Therapeutics
 May 12, 2025 HOLD Strong Buy
+81.2% avg upside
6 analysts
 — +50.1%
CARM
Carisma Therapeutics
 May 12, 2025 HOLD Buy
+15294.7% avg upside
11 analysts
 — -99.8%
IMCR
Immunocore Holdings
 Nov 06, 2024 BUY Strong Buy
+124.5% avg upside
22 analysts
$84.00
193.62% Upside
 -5.7%
CLLS
Cellectis SA
 Nov 05, 2024 BUY Strong Buy
+569.9% avg upside
16 analysts
$10.00
235.53% Upside
 +83.2%
BMRN
BioMarin Pharmaceutical
 Oct 30, 2024 HOLD Strong Buy
+72.7% avg upside
52 analysts
$65.00
18.91% Upside
 -22.1%
QTTB
Q32 Bio
 Nov 16, 2023 HOLD Buy
+345.2% avg upside
24 analysts
$27.00
126.88% Upside
 +220.0%
KRRO
Korro Bio
 Sep 26, 2023 HOLD Strong Buy
+108.3% avg upside
19 analysts
$25.00
92.55% Upside
 +78.7%
🔒 15 more ratings — with price targets, crowd consensus and our measured returns.
Sign in free to unlock See Pro plans
Free account unlocks every analyst's full coverage table.
Jack Allen — Frequently Asked Questions
How accurate are Jack Allen's stock ratings?
Based on the calls 13Foresight could measure, about 50% of Jack's ratings were profitable over a one-year hold, with an average return of +16.8% per rating, or +0.9% versus the S&P 500. We score every analyst the same way, from historical prices.
How is Jack ranked on 13Foresight?
Jack Allen is currently ranked #1800 with a 3-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does Jack cover?
Jack most recently has ratings on LYEL, NTLA, ALLO, RARE, TIL, MREO, VOR, CRSP, TSHA, LCTX, EDIT, VYGR and 8 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.